 Abstract mybomian gland dysfunction, MGD, is a common condition that leads to dry eye syndrome, DES, which is characterized by reduced tear film stability and increased evaporation of tears. Treatment options include eyelid hygiene, warm eye masks, oculolubricants, manual expression, micro blepharoxfoliation, thermal pulsation, intense pulsed light, intraductal probing, topical ophthalmic prescriptions, and November 3, under review with the U.S. Food and Drug Administration November 3 is the most advanced emerging therapy for desassociated with MGD and has shown promising results in randomized controlled trials. Further research is necessary to determine its effectiveness and safety in treating desassociated with MGD. This article was authored by John D. Shepard and Kelly K. Nichols.